Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to dissemintate knowledge & skills of Acute Cardiovascular Care
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission: To promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our goal is to reduce the burden in cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our Mission is "to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death"
To improve quality of life and logevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
Working Groups goals is to stimulate and disseminate scientific knowledge in different fields of cardiology.
ESC Councils goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Prof. Christian Joseph Marie Vrints
View the Slides from this session in ESC Congress 365
Although the incidence of cardiogenic shock has declined and outcome has markedly improved due to the routine use of primary PCI in the management of STEMI, it still remains associated with an unacceptably high mortality rate (50%).
Alexander Lyon (London, UK) provided an update on the use of inotropic support in cardiogenic shock. Although they are systematically used, there is limited evidence on their use during cardiogenic shock. There clearly is a clinical need for innovative drugs that stimulate the heart without further harming the surviving myocardium. Ryanodine receptor stabilizers that reduce the calcium leak from the sarcoplasmatic reticulum are a new class of inotropic drugs that may be helpful in the management of cardiogenic shock.
Alain Combes (Paris, FR) proposed an earlier application of an extracorporeal membrane oxygenator (ECMO) as first-line therapy in the management of cardiogenic shock. ECMO is less expensive, more versatile and easier to set up than the expensive surgical ventricular assist devices (VAD). The early institution of mechanical support with ECMO may prevent the development of multi-organ failure. This new strategy will tested in the Anchor trial. Early institution of mechanical support can be facilitated by a mobile ECMO team that operates within a network of hospitals. The ECMO machine can be brought to patients in the peripheral community hospitals, allowing a more safe transport to the central, expert hospital. This innovative approach is under evaluation in a hospital network in Paris.
The majority of the STEMI patients with cardiogenic shock have multivessel disease. Although the guidelines recommend performing complete revascularization, there is no evidence that this is associated with a better outcome than performing PCI only of the culprit vessel. Uwe Zeymer (Ludwigshaven, DE) presented the results of recent registry and a post hoc analysis of the IABP shock trial that suggest that PCI of the culprit lesion, followed by a staged procedure could be the best strategy. This will be compared to a complete revascularisation strategy in the CULPRIT-Shock trial.
Development of multi-organ failure is a frequent lethal complication in patients with cardiogenic shock. Pascal Vranckx (Hasselt, BE) emphasized the importance of early recognition of this. Action should be taken early to restore both the macro- and the micro-circulation in order to prevent failure of the "big five" (lungs, intestine, kidney, liver and brain).
Paradoxically, administration of nitrates can be used to improve the microcirculation in cardiogenic shock and a single shot of a broad spectrum antiobiotic may prevent the development of sepsis due to translocation of intestinal bacteria.
STEMI complicated by cardiogenic shock